Sponsor of the Day:
Jerkmate
https://www.biospace.com/business/after-mortality-marred-year-sarepta-looks-ahead-to-catalyst-rich-2026
After Mortality-Marred Year, Sarepta Looks Ahead to Catalyst-Rich 2026 - BioSpace
Jan 13, 2026 - Jefferies analysts forecast a $1 billion market opportunity for each of Sarepta’s siRNA programs for facioscapulohumeral muscular dystrophy and myotonic...
looks ahead2026 biospacemortalitymarredyear
https://www.biospace.com/fda/6-fda-decisions-to-watch-in-q2-2026
6 FDA Decisions To Watch in Q2 2026 - BioSpace
Mar 31, 2026 - The FDA has some big verdicts lined up in the second quarter, including one for a closely watched obesity drug that many anticipate will further intensify...
fda decisionsq2 2026watchbiospace
https://www.biospace.com/nextgen
NextGen: Class of 2026 - BioSpace
Jan 12, 2026 - The top life sciences startups to watch this year
nextgen class2026 biospace
https://www.biospace.com/fda/6-fda-decisions-to-watch-in-q1-2026
6 FDA Decisions To Watch in Q1 2026 - BioSpace
Jan 12, 2026 - After greenlighting 56 novel therapeutics in 2025, four notable applications continue to await the agency’s action after being delayed from the fourth quarter...
fda decisionsq1 2026watchbiospace